Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Pre-clinical studies support that targeting high-risk myeloma genotypes with optimized CD27-based anti-CD70 CAR-T alone, or in dual constructs including BCMA, could be promising strategy based on in vitro and in vivo efficacy.”
Title: Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells
Authors: Corynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, Amrik Singh Kang, Nikhil Chilakapati, Naomi Akagi, Ananya Mishu Manoj, Haley Johnson, Tasfia Rashid, Juwita Werner, Abhilash Barpanda, Huimin Geng, Yu-Hsiu Tony Lin, Sham Rampersaud, Daniel Gil-Alós, Amin Sobh, Daphné Dupéré-Richer, Adolfo Aleman, Gianina Wicaksono, K.M. Kawehi Kelii, Radhika Dalal, Emilio Ramos, Anjanaa Vijayanarayanan, Kiran Lakhani, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, ons Zakraoui, Isa Tariq, Ajai Chari, Alfred Chung, Anupama Deepa Kumar, Thomas Martin, Jeffrey Lee Wolf, Sandy Wong, Veronica Steri, Mala Shanmugam, Lawrence H Boise, Tanja Kortemme, Samir Parekh, Elliot Stieglitz, Jonathan D Licht, William Karlon, Benjamin G Barwick, Arun Wiita.
You can read the Full Article in Blood.
More posts featuring Robert Orlowski.
